IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
venetoclax Sensitive: A2 - Guideline
EHA 2022 - 4 days (NewA2)
|
venetoclax Sensitive: A2 - Guideline
EHA 2022 - 4 days - (New C3)
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
EHA 2022 - 4 days (NewC3)
|
cytarabine / daunorubicin liposomal formulation Sensitive: C3 – Early Trials
EHA 2022 - 4 days - (New C3)
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
ivosidenib Sensitive: A1 - Approval
N Engl J Med - 3 weeks (NewA1)
|
ivosidenib Sensitive: A1 - Approval
N Engl J Med - 3 weeks - (New B)
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
ivosidenib Sensitive: A1 - Approval
|
ivosidenib Sensitive: A1 - Approval
|
IDH1 mutation
|
Sarcoma
|
IDH1 mutation
|
Sarcoma
|
ivosidenib Sensitive: A2 - Guideline
|
ivosidenib Sensitive: A2 - Guideline
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
temozolomide gel Sensitive: B - Late Trials
|
temozolomide gel Sensitive: B - Late Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
gilteritinib Resistant: B - Late Trials
|
gilteritinib Resistant: B - Late Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
PCV Sensitive: B - Late Trials
|
PCV Sensitive: B - Late Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
ivosidenib Sensitive: C1 - Off-label
|
ivosidenib Sensitive: C1 - Off-label
|
IDH1 mutation
|
Astrocytoma
|
IDH1 mutation
|
Astrocytoma
|
temozolomide Sensitive: C2 – Inclusion Criteria
|
temozolomide Sensitive: C2 – Inclusion Criteria
|
IDH1 mutation
|
GBM
|
IDH1 mutation
|
GBM
|
temozolomide Sensitive: C2 – Inclusion Criteria
|
temozolomide Sensitive: C2 – Inclusion Criteria
|
IDH1 mutation
|
GBM
|
IDH1 mutation
|
GBM
|
NEO100 Sensitive: C2 – Inclusion Criteria
|
NEO100 Sensitive: C2 – Inclusion Criteria
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
AG-881 Sensitive: C2 – Inclusion Criteria
|
AG-881 Sensitive: C2 – Inclusion Criteria
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
TG02 Sensitive: C3 – Early Trials
|
TG02 Sensitive: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
venetoclax + ABBV-621 Sensitive: C3 – Early Trials
|
venetoclax + ABBV-621 Sensitive: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
venetoclax + ivosidenib Sensitive: C3 – Early Trials
|
venetoclax + ivosidenib Sensitive: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
FT-2102 Sensitive: C3 – Early Trials
|
FT-2102 Sensitive: C3 – Early Trials
|
IDH1 mutation
|
GBM
|
IDH1 mutation
|
GBM
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
CFI-400945 Sensitive: C3 – Early Trials
|
CFI-400945 Sensitive: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
venetoclax + midostaurin Resistant: C3 – Early Trials
|
venetoclax + midostaurin Resistant: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
venetoclax + gilteritinib Resistant: C3 – Early Trials
|
venetoclax + gilteritinib Resistant: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
venetoclax + sorafenib Resistant: C3 – Early Trials
|
venetoclax + sorafenib Resistant: C3 – Early Trials
|
IDH1 mutation
|
CMML
|
IDH1 mutation
|
CMML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
BAY1436032 Sensitive: C3 – Early Trials
|
BAY1436032 Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Anaplastic Astrocytoma
|
IDH1 mutation
|
Anaplastic Astrocytoma
|
PCV Sensitive: C3 – Early Trials
|
PCV Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Sarcoma
|
IDH1 mutation
|
Sarcoma
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
IDH1 mutation
|
MDS
|
IDH1 mutation
|
MDS
|
venetoclax + ivosidenib Sensitive: C3 – Early Trials
|
venetoclax + ivosidenib Sensitive: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
MEN1703 Sensitive: C3 – Early Trials
|
MEN1703 Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
metformin Sensitive: C3 – Early Trials
|
metformin Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Sarcoma
|
IDH1 mutation
|
Sarcoma
|
metformin Sensitive: C3 – Early Trials
|
metformin Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
metformin Sensitive: C3 – Early Trials
|
metformin Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Biliary Tract Cancer
|
IDH1 mutation
|
Biliary Tract Cancer
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
CDIAG Sensitive: C3 – Early Trials
|
CDIAG Sensitive: C3 – Early Trials
|
IDH1 mutation
|
GBM
|
IDH1 mutation
|
GBM
|
AV-GBM-1 Sensitive: C3 – Early Trials
|
AV-GBM-1 Sensitive: C3 – Early Trials
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
ABBV-744 Sensitive: D – Preclinical
|
ABBV-744 Sensitive: D – Preclinical
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
venetoclax + IACS-010759 Sensitive: D – Preclinical
|
venetoclax + IACS-010759 Sensitive: D – Preclinical
|
IDH1 mutation
|
GBM
|
IDH1 mutation
|
GBM
|
panobinostat Sensitive: D – Preclinical
|
panobinostat Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
pamiparib Sensitive: D – Preclinical
|
pamiparib Sensitive: D – Preclinical
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
AZD0530 Sensitive: D – Preclinical
|
AZD0530 Sensitive: D – Preclinical
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
bosutinib Sensitive: D – Preclinical
|
bosutinib Sensitive: D – Preclinical
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
APO866 Sensitive: D – Preclinical
|
APO866 Sensitive: D – Preclinical
|
IDH1 mutation
|
Leukemia
|
IDH1 mutation
|
Leukemia
|
venetoclax Sensitive: D – Preclinical
|
venetoclax Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
sunitinib Sensitive: D – Preclinical
|
sunitinib Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
bevacizumab Sensitive: D – Preclinical
|
bevacizumab Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
panobinostat Sensitive: D – Preclinical
|
panobinostat Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
NPI-0052 Sensitive: D – Preclinical
|
NPI-0052 Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
omacetaxine mepesuccinate Sensitive: D – Preclinical
|
omacetaxine mepesuccinate Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
regorafenib Sensitive: D – Preclinical
|
regorafenib Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
dactinomycin Sensitive: D – Preclinical
|
dactinomycin Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
romidepsin Sensitive: D – Preclinical
|
romidepsin Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
daunorubicin Sensitive: D – Preclinical
|
daunorubicin Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
teniposide Sensitive: D – Preclinical
|
teniposide Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
gemcitabine Sensitive: D – Preclinical
|
gemcitabine Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
paclitaxel Sensitive: D – Preclinical
|
paclitaxel Sensitive: D – Preclinical
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
decitabine Sensitive: D – Preclinical
|
decitabine Sensitive: D – Preclinical
|